Recent 8-K filings for ARVN

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 12, 2026 11:15 UTC earnings item 2.02item 9.01

  Arvinas reports Q1 2026; FDA approves first PROTAC VEPPANU; licenses to Rigel

• May 12, 2026 11:14 UTC m_and_a item 1.01item 7.01item 9.01

  Arvinas and Pfizer out-license VEPPANU to Rigel for $85M upfront; potential $320M milestones

source · ARVN on sec.gov